Adalvo will submit the DCP for Palbociclib Film-coated Tablets in November 2024.
This submission will strengthen Adalvo’s oncology portfolio, which is backed by our robust IP strategy and aims to guarantee rapid market access.
Based on the reference brand Ibrance, Palbociclib targets HR-positive and HER2-negative breast cancer. Ibrance, the first FDA-approved drug in its class, had global sales of $5.8 billion in 2023, with a 3-year CAGR of 4%, according to IQVIA.
There are no half-measures at Adalvo – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Partner Up Now!